Overall, these findings demonstrated that MYC overexpression in JHU22 HNSCC cells significantly reduced the trametinib-induced cell cycle arrest, thereby promoting cell cycle progression while enhancing the apoptotic response to trametinib treatment. The gene discussed is MYC; the disease is head and neck squamous cell carcinoma.